• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA accepts AcelRx’s NDA for Dsuvia pain reliever

February 27, 2017 By Sarah Faulkner

AcelRx PharmaceuticalsFDA accepts AcelRx's NDA for Dsuvia pain reliever (NSDQ:ACRX) said today that the FDA accepted the company’s New Drug Application for its Dsuvia pain relief therapy. The federal watchdog set a target decision date for October 12 this year.

The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator to patients with moderate-to-severe acute pain resulting from trauma or injury.

Dsuvia is investigational and not approved in any country.

“It is truly gratifying to see years of work developing a sublingual formulation of sufentanil and conducting multiple clinical trials finally come to this stage,” co-founder & chief medical officer Dr. Pamela Palmer said in prepared remarks. “We believe that Dsuvia will provide physicians and their patients a non-invasive treatment alternative in emergency medicine and short-stay or ambulatory surgeries for the treatment of moderate-to-severe acute pain.”

The Redwood City, Calif.-based company’s NDA was supported by the sufentanil tablet’s clinical program, which included 4 clinical trials evaluating the sublingual painkiller as a treatment for acute pain in postoperative and emergency department patients. The data showed that patients treated with the sufentanil therapy demonstrated alleviation from pain as early as 15 minutes after they were dosed. Adverse events associated with treatment were similar to that of opioid therapy – nausea, headache, vomiting and dizziness.

Earlier this month, AcelRx touted data from case studies, including a 26-year old female with a 2nd degree burn on the right thigh, as well as a 49-year old male with 2nd and 3rd degree burns covering 13% of his body.

Along a 10 point scale, both patients reported a baseline pain intensity of 8. After 1 dose of Dsuvia, both patients reported a 2 point decrease in pain intensity within 15 minutes, the company said.

In the trial, the majority of patients reported no adverse events, according to AcelRx, but those that did reported nausea, somnolence and vomiting.

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Regulatory/Compliance, Sublingual films Tagged With: AcelRx

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS